Fresenius, the giant German maker of dialysis services and products, said Monday that it will buy APP Pharmaceuticals for for about $4.6 billion including debt, giving it control of one of the biggest makers of generic injectable drugs.
Fresenius, the giant German maker of dialysis services and products, said Monday that it will buy APP Pharmaceuticals for for about $4.6 billion including debt, giving it control of one of the biggest makers of generic injectable drugs.
Under the terms of the deal, Fresenius will pay $23 a share for APP, a 29 percent premium over APP’s closing stock price on Thursday. The deal also includes a provision known as an earnout, under which Fresenius would pay up to an additional $6 a share, or $970 million, if APP reaches certain financial targets.